APA KATA PAKAR-PAKAR?

Researchers at Ohio State University Medical Center (Columbus, Ohio), University of Kuopio (Kuopio, Finland), and Creighton University Medical Center (Omaha, Neb.) have shown that OptiBerry significantly inhibits angiogenesis both in vitro and in vivo, thus offering potential benefit in the treatment of related disorders such as cancer and inflammation. The studies were published in Free Radical Research and the Federation of European Biochemical Societies (FEBS) Letters

http://newhope360.com/supply-news-amp-analysis/interhealths-optiberry-shown-inhibit-angiogenesis

Keselamatan dan keberkesanan Optiberry terbukti menerusi kajian klinikal universiti-universiti terkemuka dunia:

Ohio State University Medical Center
University of Nebraska Medical Center
Creighton University Medical Center
Harvard Medical School
Georgetown University Medical Center
Universities of California (Berkeley and Davis)
University of Texas, Department of Health Education
University of Houston, College of Pharmacy
University of Connecticut Medical Center
Long Island University, School of Pharmacy
Auburn University, Human Performance Laboratory
Murray State University, Veterinary Center
Scranton University, Department of Chemistry